Billionaire Chris Rokos is Selling These 5 Stocks in 2023
In this article, we discuss billionaire Chris Rokos is selling these 5 stocks in 2023.
Prometheus Biosciences Inc. (RXDX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Polar Capital Brian Ashford-Russell And Tim Woolley | 0 | $0 | 0% | |
| 2. | Perceptive Advisors Joseph Edelman | 0 | $0 | 0% | |
| 3. | Schonfeld Strategic Advisors Ryan Tolkin (Cio) | 0 | $0 | 0% | |
| 4. | 0 | $0 | 0% | ||
| 5. | AQR Capital Management Cliff Asness | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $19.00 | 375,000 | Other | 2,223,022 | 2021-03-16 | Filing | |
| $19.00 | 800,000 | Other | 2,648,024 | 2021-03-16 | Filing | |
| $19.00 | 14,000 | Officer | 14,000 | 2021-03-16 | Filing | |
| $19.00 | 15,000 | Director | 15,000 | 2021-03-16 | Filing | |
| $19.00 | 500 | Director | 500 | 2021-03-16 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $108.42 | 10,000 | Officer | 9,811 | 2023-04-05 | Filing | |
| $116.14 | 25,000 | Officer, Director | 55,144 | 2023-03-15 | Filing | |
| $122.13 | 10,000 | Officer | 9,811 | 2023-03-06 | Filing | |
| $114.59 | 865,000 | Large Shareholder | 4,001,132 | 2023-03-08 | Filing | |
| $125.13 | 10,620 | Officer, Director | 55,144 | 2023-03-03 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 0 | $0 | 0% | |
| 2. | 0 | $0 | 0% | |
| 3. | 0 | $0 | 0% | |
| 4. | 0 | $0 | 0% | |
| 5. | 0 | $0 | 0% |
News See All
What Makes Prometheus Biosciences (RXDX) an Attractive Investment Choice?
Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2023 investor letter. A copy of the same can be downloaded here.
Positive Clinical Trial Results Pushed Prometheus Biosciences (RXDX) in Q4
Alger Capital, an investment management company, released its “Alger Small Cap Focus Fund” fourth quarter investor letter. A copy of the same can be downloaded here.
5 Best Performing Biotech Stocks in 2022
Verona Pharma plc (NASDAQ:VRNA) is a London-based clinical stage biopharmaceutical company, focused on development and commercialization of therapies for the treatment of respiratory diseases with unmet...
12 Best Multibagger Stocks to Buy Now
In this uncertain market backdrop, investors are focused on macroeconomic and geopolitical constraints and their potential effects on investment portfolios. Goldman Sachs believes the U.S.
5 Best Small-Cap Stocks To Buy Now
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is a California-based surgical robotics company that develops transformative solutions in urology.
5 Best IPO Stocks to Invest In Right Now
In this piece, we will take a look at the five best stocks that have recently had their initial public offering.
5 Biotech Stocks to Buy Today According to Kerr Neilson's Platinum Asset Management
In this piece, we will take a look at the five biotechnology stocks to buy today according to Kerr Neilson's Platinum Asset Management.
5 Pharmaceutical Stocks to Buy Now According to Billionaire Kerr Neilson
In this article, we will look at 5 pharmaceutical stocks to buy now according to billionaire Kerr Neilson.
Billionaire Hedge Funds
